Why the study?
Does intensive lipid-lowering therapy with atorvastatin and ezetimibe improve neurocognitive functions and reduce inflammatory burden in older patients with atrial fibrillation?
Does intensive lipid-lowering therapy with atorvastatin and ezetimibe improve neurocognitive functions and reduce inflammatory burden in older patients with atrial fibrillation?
Intensive lipid-lowering therapy in older AF patients may reduce inflammatory burden, which correlates with preserved neurocognitive function and brain volume.
Answers are grounded in this paper and cite their sources.
May support intensive lipid-lowering in older AF for inflammation-linked neuroprotection; extends cardiovascular trials to brain volume and cognitive endpoints.
BACKGROUND: Atrial fibrillation (AF) is associated with increased mortality and morbidity, including risk for cerebral macro- and microinfarctions and cognitive decline, even in the presence of adequate oral anticoagulation. AF is strongly related to increased inflammatory activity whereby anti-inflammatory agents can reduce the risk of new or recurrent AF. However, it is not known whether anti-inflammatory therapy can also modify the deterioration of neurocognitive function in older patients with AF. In the present study, older patients with AF were treated with intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg, or placebo. We examined the relationship between neurocognitive functions and inflammatory burden. FINDINGS: Analysis of inflammatory markers revealed significant reductions in high sensitivity C-reactive protein (hs-CRP), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor antagonist (IL-1RA), interleukin (IL)-9, IL-13 and IL-17, and interferon-γ (IFNγ) in the treatment group compared to placebo. Reduction in plasma concentration of IL-1RA, IL-2, IL-9 and IL-12, and macrophage inflammatory protein-1β (MIP-1β) correlated significantly with improvement in the neurocognitive functions memory and speed. Loss of volume in amygdala and hippocampus, as determined by magnetic resonance imaging (MRI), was reduced in the treatment arm, statistically significant for left amygdala. CONCLUSIONS: Anti-inflammatory therapy through intensive lipid-lowering treatment with atorvastatin 40 mg and ezetimibe 10 mg can modify the deterioration of neurocognitive function, and the loss of volume in certain cerebral areas in older patients with AF. TRIAL REGISTRATION ClinicalTrials.gov: NCT00449410.
No takes yet. Share an insight, caveat, or question.
Lappegård et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: